Chemotherapy and surgery in a murine osteosarcoma

Area of Science:

• Oncology
• Surgical Oncology
• Pharmacology

Background:

• Pulmonary metastatic disease is a significant challenge in osteosarcoma treatment.
• Evaluating the combined effects of surgery and chemotherapy is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy of doxorubicin and cisplatin in managing pulmonary metastases in a murine osteosarcoma model.
• To investigate the impact of perioperative chemotherapy administration on disease-free survival.
• To develop and utilize a model of recurrent primary and metastatic disease to study treatment responses.

Main Methods:

• Murine osteosarcoma model (MGH-OGS) was used to evaluate surgical and chemotherapeutic interventions.
• Doxorubicin and cisplatin were administered at specific dosages and schedules.
• A model with recurrent primary and metastatic disease was established through marginal resection and regrowth.
• Amputation or resection of the recurrent primary tumor was performed in the recurrent model.

Main Results:

• Doxorubicin showed efficacy in delaying tumor growth, while cisplatin was ineffective.
• Perioperative administration of doxorubicin (one of three doses given at surgery) enhanced disease-free survival.
• Resection of the recurrent primary tumor accelerated pulmonary metastatic growth.
• Doxorubicin's effect on pulmonary metastases was enhanced when administered at the time of amputation in the recurrent model.

Conclusions:

• Perioperative chemotherapy, specifically doxorubicin, can improve outcomes in osteosarcoma.
• The timing of chemotherapy relative to surgical intervention significantly influences treatment efficacy.
• A model of recurrent disease is valuable for studying the interplay between primary tumor burden and metastatic progression.